文献速递头颈部肿瘤放疗

头颈部放疗后放射性骨坏死发生率:超越数字本身

Osteoradionecrosis Rates After Head and Neck Radiation Therapy: Beyond the Numbers.
PubMed 文献 · Pract Radiat Oncol · 2024-04-20

本文综述了头颈部放疗后放射性骨坏死(ORN)报道发生率差异大的原因,指出定义、分级、纳入标准和治疗参数的异质性均可显著影响ORN发生率的报告,临床需结合背景理解真实风险。

要点

  • 文献报道的ORN发生率范围广,从0%至高达20%。
  • ORN定义、分级、研究纳入标准和治疗参数的异质性均可显著影响发生率报告。
  • 需深入理解ORN发生率背后的临床背景以把握真实风险。

核心结论

  • 多种因素可影响ORN的报道发生率,需全面理解其背后的临床背景以认识这一重要放疗毒性的真实风险。

研究设计与样本

  • 本文为综述,总结了导致ORN报道发生率高度变异的因素。

主要发现

  • 近期文献报道的ORN发生率范围为0%至高达20%。
  • 可变的定义、可变的分级以及研究纳入标准和治疗参数的异质性均可显著影响ORN发生率的报告。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Osteoradionecrosis (ORN) is a severe late complication of head and neck radiation therapy shown to have profound negative effect on the quality of life of cancer survivors. Over the past few decades, improvements in radiation delivery techniques have resulted in a decrease in the incidence of ORN. However, even with modern radiation therapy techniques, ORN remains an important clinical concern. In recent literature, there is a wide range of reported ORN rates from 0% to as high as 20%. With such a high level of variability in the reported incidence of ORN, oncologists often encounter difficulties estimating the risk of this serious radiation therapy toxicity. METHODS AND MATERIALS: In this review, the authors present a summary of the factors that contribute to the high level of variability in the reported incidence of ORN. RESULTS: Variable definition, variable grading, and heterogeneity of both study inclusion criteria and treatment parameters can each significantly influence the reporting of ORN rates. CONCLUSIONS: Given numerous factors can affect the reported incidence of ORN, a thorough understanding of the clinical context behind the reported ORN rates is needed to comprehend the true risk of this important radiation therapy toxicity.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang F, Wong RJ, Zakeri K, et al. Osteoradionecrosis Rates After Head and Neck Radiation Therapy: Beyond the Numbers. Pract Radiat Oncol. 2024. PMID: 38649030. doi:10.1016/j.prro.2024.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。